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Abstract
Background: The correlation between treatment satisfaction and demographic characteristics, symptoms, or health-
related quality of life (HRQL) in patients with gastroesophageal reflux disease (GERD) is unknown. The objective of this
study was to assess correlates of treatment satisfaction in patients with GERD receiving a proton pump inhibitor,
esomeprazole.
Methods:  Adult GERD patients (n = 217) completed demography, symptom, HRQL, and treatment satisfaction
questionnaires at baseline and/or after treatment with esomeprazole 40 mg once daily for 4 weeks. We used multiple
linear regressions with treatment satisfaction as the dependent variable and demographic characteristics, baseline
symptoms, baseline HRQL, and change scores in HRQL as independent variables.
Results:  Among the demographic variables only Caucasian ethnicity was positively associated with treatment
satisfaction. Greater vitality assessed by the Quality of Life in Reflux and Dyspepsia (QOLRAD) and worse heartburn
assessed by a four-symptom scale at baseline, were associated with greater treatment satisfaction. The greater the
improvement on the QOLRAD vitality (change score), the more likely the patient is to be satisfied with the treatment.
Conclusions: Ethnicity, baseline vitality, baseline heartburn severity, and change in QOLRAD vitality correlate with
treatment satisfaction in patients with GERD.
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Background
The inclusion of patients' opinions in the assessment of
interventions has gained greater prominence over the last
decades. Regulator agencies now call for the inclusion of
patient-reported outcomes (PRO) in clinical trials evaluat-
ing pharmaceuticals interventions [1-4]. PRO of interest
include health-related quality of life (HRQL), symptom
assessment, and more recently, treatment satisfaction, in
gastroesophageal reflux disease (GERD).
Whereas HRQL measures the patient's physical, psycho-
logical, and social level of function, treatment satisfaction
assesses the patient's attitude towards the treatment, or
the extent to which the patient is satisfied or not with the
results of the treatment. Thus, treatment satisfaction
focuses on the interaction of expectations and preferences
for treatments and is defined as the individual's rating of
important attributes of the process and outcomes of the
treatment experience [5]. Coyne and co-workers [6] have
summarized a number of patient important domains that
describe satisfaction with treatment including symptom
relief, flexibility with dosing, and treatment expectations.
Treatment satisfaction is also associated with prescription
regimens that involve less invasive dosing regimens [5,7-
10], such as daily versus twice daily use [11].
Evaluating treatment satisfaction may assist healthcare
providers in understanding the issues that influence
adherence with therapeutic interventions. In addition,
treatment satisfaction can be a useful PRO when treat-
ments show similar efficacy because differences in satis-
faction could lead to patient preferences for one treatment
over another and greater adherence with various treat-
ment regimens.
Demographic variables such as age, ethnicity, and gender
may influence satisfaction [12]. Older people tend to be
more satisfied with medical care than younger people [13-
15], and Caucasian people on the whole are more satis-
fied than non-Caucasians [16]. In contrast, gender does
not appear to influence treatment satisfaction [17].
The objectives of this study were to assess correlates of
treatment satisfaction, including demographic factors,
symptoms, and HRQL, as well as change scores in PRO
instruments in patients with moderate to severe GERD
receiving a proton pump inhibitor, esomeprazole.
Methods
Participants
No statistical determination of sample size has been done
since the study is of exploratory nature. We enrolled 249
patients with GERD in 13 gastroenterology practices and
four general practices across Canada between March 2002
and March 2003.
Included patients were 18 years of age or older and had a
diagnosis of moderate to severe GERD and presence of
symptoms for three months or longer [18]. Prior to inclu-
sion all patients gave written informed consent in accord-
ance with the Helsinki declaration. Of 249 patients, 217
(87%) completed the study. We excluded twelve patients
because upon review they did not meet the initial inclu-
sion criteria. Of the 20 patients who withdrew after the
baseline visit, 4 withdrew because of adverse events, 2
were unwilling to continue, 4 were lost to follow-up and
10 were excluded because of improper administration or
completion of the questionnaires at one visit. Figure 1
shows the flow of patients through the study. The final
group of 217 completed patients received four weeks of
therapy with esomeprazole 40 mg once daily, in the
morning.
Procedure
Patients completed PRO instruments at the clinic before
and approximately 28 days after treatment. The com-
pleted PRO instruments included the Quality of Life in
Reflux and Dyspepsia (QOLRAD) [19], the Feeling Ther-
mometer (FT) [20], a four symptoms scale, the Standard
Gamble (SG) [21], and an upper gastrointestinal (GI)
symptom severity scale at baseline and follow-up. Patients
completed the Health Utilities Index Mark 2 and 3 (HUI2
Flow chart Figure 1
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and HUI3) [22], and the Medical Outcomes Short-Form
36 (SF-36) [23] at baseline only; and the treatment satis-
faction item at follow-up only. We describe these instru-
ments below. In addition, trained research assistants
collected information concerning demographic data and
clinical data. Each visit lasted approximately 80 minutes.
Treatment satisfaction
Patients rated their satisfaction with treatment on a seven
point scale responding to the question: 'How satisfied are
you with the study treatment you received?' with the
response options: completely satisfied, very satisfied,
quite satisfied, no change, dissatisfied, very dissatisfied,
and completely dissatisfied.
PRO instruments
QOLRAD
The QOLRAD is a 25-item disease-specific self-adminis-
tered instrument asking about the impact of heartburn
and acid regurgitation on the patient's HRQL during the
previous week. The QOLRAD includes questions related
to 5 domains; emotional distress, sleep disturbance, prob-
lems with food and drink, limitations in physical and
social functioning, and lack of vitality. Patients respond to
each question on a seven-point scale on which a higher
score indicates better HRQL. The psychometric properties
concerning validity, reliability, and responsiveness to
change are reported elsewhere [19,24]. The minimal
important difference (MID) that patients perceive as
important is approximately 0.5 on the 1 – 7 scale [25].
FT
The FT is a visual analogue scale that resembles a ther-
mometer. It is divided into 100 segments with a mark to
represent each segment. Its anchors are dead (0) and full
health (100) [21]. Patients mark their own health state
and/or that of hypothetical patient scenarios or clinical
marker states. In this study, three patient scenarios repre-
sented mild, moderate, and severe GERD. We developed
and tested the clincal marker states with patients and cli-
nicians [26]. The MID of the FT is approximately 6 on the
0 to 100 scale [27].
HUI
This is a 15 item questionnaire designed to quantify
HRQL [22]. Each item has 4–6 response options. There
are 8 attributes in the HUI3 classification system: vision,
hearing, speech, ambulation, dexterity, emotion, cogni-
tion, and pain. In the HUI2 there are 7 attributes: sensa-
tion, mobility, emotion, cognition, self-care, pain, and
fertility.
SF-36
The SF-36 contains 36 items that measure 8 dimensions:
physical functioning, role limitations due to physical
health problems, bodily pain, general health perceptions,
vitality, social functioning, role limitations due to emo-
tional problems, and general mental health. This ques-
tionnaire has been extensively tested for validation and
reliability [23]. Each domain is scored on a 0 to 100 scale
where higher scores indicate better HRQL. Scores on the
SF-36 can also be expressed as two summary measures,
the physical component score and the mental component
score, which provide a measure of the overall effect of
physical and mental impairment on HRQL.
Rating of four symptoms
To assess common symptoms in GERD, patients evalu-
ated their heartburn, acid reflux, stomach pain, and belch-
ing for the past week using a seven-point scale ranging
from no discomfort to very severe discomfort.
SG
The SG involves decision in the face of uncertainty, where
in the standard administration the uncertainty involves a
risk of death. The SG offers the patients two alternatives
from which a choice must be made: Choice A is a hypo-
thetical treatment with two possible outcomes: 1) return-
ing to full health (probability p) for t years, at the end of
which they die, or 2) immediate death (probability 1 – p).
The alternative (choice B) is a certain outcome that he or
she will stay in a health state (their own health state, or a
patient scenario) for t years until death. t varies depending
on the patient's age. The interviewer used a change board
with the ping-pong approach varying the probability p in
steps of 0.05 to find the value p where the respondent
considered choice A = choice B. This value of p is the util-
ity value for the health state in choice A in the interval
from dead (0) to full health (1). The greater a patient's
willingness to accept the risk of a worse outcome (e.g.
dead) to avoid the health state in choice A, then the lower
is the utility of the state in choice A to them.
Rating of upper GI symptom severity
Patients documented the severity of overall upper GI
symptom on a seven-graded scale (1 = no symptoms; 7 =
severe symptoms) over the past seven days. At baseline,
patients who had no, minimal or mild symptoms were
not included in this study.
Statistical analyses
We calculated the mean and standard deviation of the
basic demographic variables. Our multiple linear regres-
sion analysis focused on the outcome variable treatment
satisfaction, which we treated as a continuous outcome
variable. Evaluation of the data with polynomial regres-
sion yielded similar results. Potential correlates were
demographic variables and baseline scores, as well as
change scores for the PRO instruments described in the
previous section. We first modelled these variablesHealth and Quality of Life Outcomes 2005, 3:4 http://www.hqlo.com/content/3/1/4
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univariately as correlates of treatment satisfaction and
only those that were significant at p < 0.1 entered into the
multiple regression model. After having entered the mul-
tiple regression model, only those significant at p < 0.05
remained in the final model.
Results
Table 1 shows the baseline demographic characteristics
and frequencies of the included patients. The mean age
was 50 years, and approximately 50% of the patients were
female. The mean number of months since diagnosis was
86 months. Approximately 70% were full-time or part-
time employed, and 88% were Caucasians.
Table 2 depicts the mean baseline scores for the QOLRAD,
the four symptoms scale, the FT, the SG, the HUI, and the
SF-36. The mean QOLRAD scores at baseline were lowest
for the food/drink domain, indicating worse HRQL for
this domain, and the mean scores at baseline for the four
symptoms show that patients had most problems with
heartburn. Furthermore, the mean SF-36 scores at base-
line were lowest (worse) for the bodily pain dimension,
and highest (best) for the social functioning domain. Fig-
ure 2 shows the distribution of the treatment satisfaction
scores. Approximately 50% of the patients were com-
pletely satisfied, 25% were very satisfied, and approxi-
mately 15% were quite satisfied. About 7% reported no
change or dissatisfaction of different severity.
Table 3 portrays the results from the multiple linear
regression analysis. Ethnicity, baseline QOLRAD vitality,
baseline heartburn from the four symptoms scale, and
QOLRAD vitality change score remained as independent
variable when all variables had entered the model.
Caucasian patients were more likely to be satisfied with
the treatment than patients of other ethnicity. Higher
baseline QOLRAD vitality scores, higher levels of heart-
burn and larger change on the QOLRAD vitality score
were associated with greater treatment satisfaction.
Discussion
The objective of this study was to assess correlates of treat-
ment satisfaction in patients with moderate to severe
GERD receiving esomeprazole. We found that Caucasian
ethnicity, greater vitality and more severe heartburn at
baseline, correlates with treatment satisfaction.
Table 1: Demographic characteristics and frequencies at 
baseline for the study sample (N = 217).
Frequency Percentage
Gender
Male 103 47.5
Female 114 52.5
Age
Mean (SD) 49.7 (13.7)
Range 20–82
Months since diagnosis
Mean (SD) 86.3 (99.4)
Range 1–504
Smoking history
Never 94 43.5
Yes 38 17.6
Previous 84 38.9
Living alone 23 10.6
Employed: full-time and part-time 149 68.7
Ethnicity
Caucasian 191 88.0
Other 26 12.0
Severity of gastroesophageal 
reflux disease (GERD)
Moderate problem 112 51.6
Moderate severe problem 74 34.1
Severe problem 27 12.5
Very severe problem 4 1.8
Table 2: Baseline scores for Quality of Life in Reflux and 
Dyspepsia (QOLRAD), four symptoms, Feeling Thermometer 
(FT), Standard Gamble (SG), Health Utilities Index Mark 2 and 3 
(HUI), and Medical Outcomes Short Form-36 (SF-36).
Mean SD
QOLRAD dimensions
Emotional distress 4.5 1.4
Sleep disturbance 4.5 1.5
Food/drink problem 3.8 1.2
Physical/social functioning 5.4 1.4
Vitality 4.3 1.3
Four symptoms
Stomach pain 3.9 1.5
Heartburn 4.5 1.2
Belching 3.6 1.6
Acid reflux 4.1 1.6
FT 0.7 0.2
SG 0.8 0.2
HUI2 0.8 0.2
HUI3 0.8 0.2
SF-36
Physical functioning 46.6 9.0
Role-physcial 45.5 11.4
Bodily pain 42.8 9.4
General health 46.2 9.7
Vitality 45.9 9.8
Social functioning 47.7 10.3
Role-emotional 46.5 12.0
Mental health 46.9 10.4
Physial component 45.1 8.7
Mental component 47.6 11.0Health and Quality of Life Outcomes 2005, 3:4 http://www.hqlo.com/content/3/1/4
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Furthermore, the greater the improvement on vitality
change score, the more likely the patient is to be satisfied
with the treatment.
The strengths of this study include the detailed assessment
of a number of demographic characteristics, HRQL and
symptoms. However, this study has two important limita-
tions. First, we did not perform a placebo controlled trial
limiting our ability to assess satisfaction as a true treat-
ment result versus other reasons for satisfaction. Second,
investigators have not conducted a thorough psychomet-
ric assessment of the treatment satisfaction instrument we
used in this study.
Distribution of treatment satisfaction scores Figure 2
Distribution of treatment satisfaction scores
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Table 3: Results from the multiple linear regression analysis with 
treatment satisfaction as outcome variable.
Correlate variables Parameter 
estimate (β)
SE P-value
Ethnicity (Caucasian vs. other) -0.570 0.190 0.003
QOLRAD Vitality baseline -0.628 0.068 <0.001
Four symptoms Heartburn -0.195 0.055 <0.001
QOLRAD Vitality change -0.593 0.071 <0.001
Note. R2 = 0.34 includes ethnicity, QOLRAD Vitality, heartburn, and 
QOLRAD Vitality change scoreHealth and Quality of Life Outcomes 2005, 3:4 http://www.hqlo.com/content/3/1/4
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Nevertheless, the present study yields four important
results. First, in this sample of GERD patients without
prior endoscopic evaluation of their symptoms, Cauca-
sian ethnicity was positively associated with treatment sat-
isfaction. Ethnic origin is perhaps one of the most
complex demographic characteristics [12] and it has pre-
viously been reported that Caucasian people on the whole
are more satisfied than non-Caucasians [16].
Second, higher vitality scores, as assessed by the QOL-
RAD, were associated with higher treatment satisfaction. A
patient's health status prior to receiving treatment may
cause the patient to be either more or less satisfied with
treatment. Clearly and McNeil [28] reported positive cor-
relations between health status and satisfaction. However,
it is unclear if satisfaction was correlated with health
status before intervention or with health status after inter-
vention. A possible interpretation of the positive associa-
tion between QOLRAD vitality and treatment satisfaction
in our study might be that patients with a high vitality
score at baseline are less distressed by their disease, and
therefore tend to be more satisfied. The association in our
study between higher vitality scores, as assessed by the
QOLRAD, and higher treatment satisfaction is in line with
Revicki and co-workers [29] who found that patients
reporting greater severity in heartburn symptoms were
more likely to report psychological distress and impaired
well-being compared with those who reported no or mild
symptoms. However, Revicki et al measured HRQL with a
generic instrument while we used a disease-specific
instrument.
Third, higher scores for heartburn, assessed with the four
symptoms scale, were related to higher treatment satisfac-
tion. Thus, in our study population, patients with high
discomfort from heartburn at baseline perceived a high
satisfaction with treatment.
Fourth, the higher the improvement on the QOLRAD
vitality (change score), the more likely the person is to be
satisfied with the treatment.
Patients' age is regarded as the most consistent determi-
nant characteristic of satisfaction [13-15]. The results from
this study did not reveal that treatment satisfaction was
related to age. However, Fitzpatrick [30,31] and Fox and
Storms [32] highlight the lack of consistency of the effect
of age in satisfaction studies. Since satisfaction studies
focused on a variety of concepts, such as satisfaction with
medical care, satisfaction with hospital management, sat-
isfaction with health services, and satisfaction with treat-
ment, it might be that the association between age and
satisfaction is dependent on the concept assessed. The lack
of an association to age reveals also the possible that our
study population was too homogenous with regard to age.
Although some studies have reported that patient gender
affects satisfaction values [33,34], other studies did not
find such association [17,35]. In line with this, in our
study population treatment satisfaction was not associ-
ated with gender.
The current results may be unique to the study sample
since no placebo control group was included in the study
and, therefore, we were unable to evaluate whether the
factors related to treatment satisfaction are related to real
treatment effects or patients' need to please and placebo
effects. The efficacy, tolerability and safety of esomepra-
zole versus other proton pump inhibitors has been shown
in other studies [36-40]. In this study, patients had mod-
erate to severe symptoms of GERD and some patients had
received proton pump inhibitors prior to this study. The
latter indicates that our study population is selected with
regard to symptom severity, and mixed with regard to pre-
vious medication, which might limit generalizability of
the findings. Treatment satisfaction in patients with mild
GERD symptoms and with no previous experience of pro-
ton pump inhibitors remains unknown.
Investigators often use several PRO instruments, each
with many dimensions and single items that are more or
less correlated in clinical studies. This can lead to a large
number of statistical tests being carried out and an
increased risk of statistically significant findings occurring
by chance in the absence of adjustment of P-values. In the
present report we did not carry out adjustments for multi-
ple comparisons for two main reasons. Firstly, the analysis
of correlations was intended to be exploratory rather than
confirmatory. Secondly, there is no consensus on how to
adjust in analyses of the nature we conducted in this
study. A simple adjustment according to Bonferroni
would be too conservative, in part because many of the
PRO variables are closely correlated.
Different drug therapies may elicit unwanted side-effects,
which could compromise the patients' HRQL, and adher-
ence with the treatment. Thus, a challenge in the
management of GERD is to achieve as high adherence as
possible. In addition, treatment satisfaction can be of use
when different drug therapies show similar efficacy since
it can lead to a preference for one drug over another and
greater adherence.
Our study also supports the need for validated treatment
satisfaction instruments because the available instru-
ments vary widely in clinical trials [41] and the majority
of studies rely on single items. There is a need for develop-
ing and improving psychometric documentation of
instruments measuring treatment satisfaction [42].Health and Quality of Life Outcomes 2005, 3:4 http://www.hqlo.com/content/3/1/4
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Conclusions
We examined correlates of treatment satisfaction, includ-
ing demographic factors, symptoms, and HRQL, as well as
change scores in HRQL, in patients with moderate to
severe GERD who were not investigated by endoscopy.
We observed that Caucasian ethnicity was positively
related to treatment satisfaction. Furthermore, higher
vitality and more severe heartburn were associated with
treatment satisfaction. Finally, the higher the improve-
ment on the QOLRAD vitality (change score), the more
likely the patient is to be satisfied with the treatment.
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